A cute respiratory failure (ARF) is a dreaded event in patients with solid tumors or hematologic malignancies (1) . ARF may occur in 10% to 50% of these patients (2, 3) and carries a mortality rate of about 50% overall and 75% when mechanical ventilation (MV) is needed (2) (3) (4) (5) (6) (7) . Over the last decade, studies have documented an increase in survival rates in patients with ARF receiving MV (5, 7). Survival was higher when noninvasive mechanical ventilation (8) was used for ventilatory support (6, 7, 9) , and lower when investigations failed to identify the cause of ARF, indicating that both diagnostic and therapeutic strategies are urgent and worthy (3, 6, 10) .
Both invasive and noninvasive diagnostic strategies can be used to identify the cause of ARF in cancer patients (1) . The invasive strategy relies on fiberoptic bronchoscopy with bronchoalveolar lavage (FO-BAL), and the noninvasive strategy on imaging studies (11, 12) and on microbiological studies of blood (13) (14) (15) (16) , urine (17, 18) , sputum (19) , and nasopharyngeal aspirates (20) . FO-BAL is currently recommended in nonhypoxemic cancer patients with pulmonary infiltrates (21, 22) . However, possible harmful effects of FO-BAL have been reported, with respiratory status deterioration in 10% to 40% of cases (1, (23) (24) (25) . Furthermore, the diagnostic yield of FO-BAL has been only 50% at best (1) . In severely hypoxemic patients, FO-BAL has been described as inadvisable or contraindicated because of the risk of deterioration in respiratory status with a subsequent need for mechanical ventilation (26, 27) .
The apparent contradiction between the need to identify the cause of ARF to improve survival and the risk of complications related to diagnostic FO-BAL has generated uncertainty about the best diagnostic strategy in hypoxemic cancer patients with ARF (1, (23) (24) (25) . No specific guidelines have been established for this situation. Neither have studies evaluated the yield of a noninvasive diagnostic strategy used as an alternative to FO-BAL (1) . We investigated practices in 15 intensive care units (ICUs) to compare diagnostic yields and mortality in cancer patients with ARF managed by noninvasive or invasive diagnostic strategies.
PATIENTS AND METHODS
The study group comprising 15 closed ICUs in university or university-affiliated hospitals in France was set up in 2003 to investigate invasive vs. noninvasive diagnostic strategies in critically ill cancer patients with ARF. The observational study reported here was approved by the appropriate ethics committee (Pitié-Salpêtrière University Hospital, Paris, France). In each ICU, an investigator used standardized forms to prospectively collect data on 10 cancer patients admitted for ARF after January 1, 2004.
ARF was defined as a respiratory rate of Ͼ30 breaths per min or respiratory distress symptoms, or PaO 2 on room air of Ͻ60 mm Hg, or the need for ventilatory support. In each of the 15 study ICUs, cancer patients are routinely managed by a multidisciplinary team that includes the referring oncologist or hematologist. For each study patient, the data reported in Tables 1-3 were collected. The Logistic Organ Dysfunction (28) score was determined at ICU admission (29) . Vital status at ICU and hospital discharge and time in the ICU and hospital were recorded for all patients. Antibiotic regimens and life-sustaining treatments were used according to current recommendations.
Bronchoscopy and BAL Procedure. Fiberoptic bronchoscopy and BAL were performed routinely as described elsewhere (30, 31) . The gross appearance of the recovered fluid was noted, with special attention to signs of hemorrhage. The fluid was placed on ice and processed immediately. Following centrifugation, the cell pellet was resuspended in cell culture medium, and smears were prepared. The smears were stained for differential cell counts, Perl Prussian blue for hemosiderincontaining alveolar macrophages (31, 32) , Grocott stain for Pneumocystis jiroveci (Toluidine blue O and May-Grunwald-Giemsa), and the Papanicolaou stain. A specific immunofluorescence test for P. jiroveci was done, as well as immunostaining for cytomegalovirus (33) . Specific polymerase chain reaction techniques were used to detect herpes viruses, syncytial respiratory viruses, and adenoviruses. Viral antigens in BAL samples were detected by a direct immunofluorescent staining method using a monoclonal antibody pool (influenza viruses A and B; parainfluenza viruses 1, 2, and 3; respiratory syncytial virus; adenovirus; and herpes simplex virus). BAL fluid aliquots were stained using Gram and Ziehl-Neelsen methods, then cultured for bacteria, mycobacteria, and fungi.
The noninvasive diagnostic strategy consisted of variable combinations of the investigations listed in Table 2 (1, 11, (13) (14) (15) (16) (17) (18) (19) (20) . Nearly all of the patients managed with FO-BAL also underwent at least one noninvasive investigation, on the basis of clinical symptoms and at the clinician's discretion.
Criteria for each Etiologic Diagnosis. Diagnoses were based on clinical, radiographic, microbiological, and cytologic findings. They were validated in each ICU by the multidisciplinary team based on predefined criteria (3, 19, 34) .
Criteria for Conventional and Noninvasive Mechanical Ventilation. When use of a highconcentration oxygen mask was not associated with a significant clinical improvement (sustained high respiratory rate [Ͼ30] or oxygen saturation below 92%), noninvasive mechanical ventilation (NIMV) was delivered to the patient through a full-face mask, as previously described (7) . NIMV was stopped when significant clinical improvement was documented. Patients in whom NIMV was not successful underwent endotracheal intubation and received conventional MV on predefined criteria (3, 7). Statistical Analysis. Results are reported as medians and quartiles (25th-75th percentiles) or numbers and percentages. Patient characteristics in the subgroups managed with noninvasive investigations vs. FO-BAL were compared using the chi-square test or Fisher's exact test, as appropriate, for categorical variables and the nonparametric Wilcoxon's ranksum test or the Kruskal-Wallis test for continuous variables. To investigate associations between patient characteristics and hospital death, use of FO-BAL, and use of conventional MV, we first performed bivariate analyses to look for a significant influence of each variable on hospital mortality by logistic regression, as measured by the estimated odds ratio (OR) with a 95% confidence interval (CI). Variables yielding p values no greater than .20 in the bivariate analyses were entered into a multiple logistic regression model in which hospital mortality was the outcome variable of interest. Finally, we estimated actuarial probabilities of survival according to the Kaplan-Meier method with log-rank tests. All tests were twosided, and p values smaller than .05 were considered statistically significant. Analyses were done using the SAS 9.1 software package (SAS Institute, Cary, NC).
RESULTS
The characteristics of the 148 patients (122 with hematologic malignancies and 26 with solid tumors) are reported in Table 1 . Forty-five (30.4%) patients had received bone marrow transplants (BMT, 27 allogeneic and 18 autologous). Chest radiograph disclosed a focal alveolar pneumonia in 22 (14.9%) patients, an interstitial pattern in 41 (27.7%), a diffuse alveolar pattern in 67 (45.3%), and nodules in eight (5.4%). Ten (6.7%) patients with neutropenia had a normal chest radiograph. High-resolution computed tomography was performed in 90 patients and disclosed ground glass opacities in 55 (61.1%) patients, nodules in 23 (25.5%), septal lines in 17 (18.9%), consolidations in 63 (70%), excavations in seven (7.8%), and halo sign in six (6.7%). Pleural effusion was found in 60 (67%) patients.
The Logistic Organ Dysfunction score at admission was 5 (3) (4) (5) (6) (7) (8) patients, leaving 20 (13.5%) patients with an undetermined diagnosis (Fig. 1) . Of the 146 identified causes, 97 were pulmonary infections, in 90 (60.8%) patients. In 23 patients, echocardiography allowed the diagnosis of cardiac pulmonary edema, and in nine recipients of hematopoietic stem cell transplantation, FO-BAL led to a diagnosis of idiopathic alveolar hemorrhage. Tests other than FO-BAL allowed the diagnosis of pulmonary involvement by the malignancy in eight patients, including five patients with pulmonary infiltration at the earliest phase of acute monocytic leukemia, two patients with bulky mediastinum and pulmonary atelectasis at the inaugural phase of lymphoma diagnosed using sternal puncture, and one patient with carcinoid lymphangitis in whom malignant cells were identified in both sputum and BAL fluid. Three patients were diagnosed with methotrexate-induced pneumonia (lymphocytic alveolitis), and in three patients beta lactam-induced pneumonia was diagnosed based on eosinophilia in the blood smears and evidence of toxic vasculitis in a skin biopsy.
Invasive and Noninvasive Diagnostic Strategies. Figure 1 reports the yields of the invasive and noninvasive diagnostic strategies. Almost all (95.3%) of the patients underwent at least one noninvasive diagnostic test, whereas FO-BAL was performed in 101 (68.2%) patients (Table 2) . Patients had a median of four (3-6) noninvasive tests within 24 hrs after ICU admission.
FO-BAL was performed at ICU admission in 25 (24.7%) patients, within 24 hrs after ICU admission in 38 (37.6%) patients, and later during the ICU stay in 38 (37.6%) patients. Of the 45 (44.5%) patients who underwent FO-BAL while not intubated, 16 had the procedure with NIMV and 29 with a high-flow oxygen mask. Patients managed with FO-BAL were younger, more frequently treated for hematologic malignancies (including allogenic BMT) than solid tumors, and more frequently had diffuse pulmonary disease with severe hypoxemia. Noninvasive diagnostic tests had a diagnostic yield of 66.7% and FO-BAL of 50.5%. FO-BAL was the only investigation that provided a diagnosis in 34 (34/101; 33.7%) patients. 2B) . Mortality was not significantly different between the groups with and without FO-BAL, and within the FO-BAL group, between the patients with and without a diagnosis (Fig. 3) . Among the 20 (13.5%) patients with an undetermined diagnosis (six in the noninvasive group and 14 in the FO-BAL group), 14 (70%) died. In addition, patients with invasive aspergillosis had a trend toward increased mortality (15.8% vs. 7.5%, p ϭ .07).
As reported in Table 3 , hospital mortality was independently affected by the characteristics of the malignancy (being higher in BMT recipients and in patients with active malignant disease), the cause of ARF (being lower in ARF during neutropenia recovery and higher in patients with an undetermined diagnosis), and the nature of life-sustaining interventions (being higher in patients who needed conventional MV or vasopressors).
DISCUSSION
In this multicenter prospective observational study, diagnostic yields and outcomes were compared between cancer patients with ARF managed using invasive vs. noninvasive investigations. FO-BAL was the only conclusive investigation in only one third of patients and induced respiratory status deterioration in about half of the cases. The noninvasive strategy had a higher diagnostic yield with no complications. Even when FO-BAL provided the diagnosis, performing this investigation did not decrease mortality but independently predicted a need for conventional MV.
Several single-center studies evaluated the diagnostic and therapeutic impact of FO-BAL in patients with various types of immunodeficiency (10, 19) . In our study, the diagnostic yield of FO-BAL was in agreement with previous reports (1) . The rate of respiratory deterioration associated with FO-BAL was at the higher end of the range reported at other centers in non ICU-patients, indicating a need for alternatives to FO-BAL in critically ill hy- poxemic patients (23) (24) (25) . Furthermore, our results suggest that FO-BAL may have been unnecessary in 70% of the patients or could, at the least, have been reserved for patients with inconclusive results of noninvasive investigations. The lack of improvement in survival of patients who underwent FO-BAL, even when this investigation provided the diagnosis, further supports greater reliance on noninvasive investigations. The noninvasive diagnostic strategy included several investigations that have been evaluated individually in cancer patients (1, 11, (13) (14) (15) (16) (17) (18) (19) (20) . In addition to evaluating each noninvasive investigation, we measured the diagnostic impact of a noninvasive strategy, defined as a variable combination of noninvasive investigations without FO-BAL (1). Given the observational study design and the use of clinical judgment to select investigations-no guidelines being availablenone of the investigations was performed routinely. Nevertheless, the noninvasive strategy yielded the diagnosis in 66.7% of patients and induced no adverse events, suggesting not only that clinicians performed only those noninvasive tests that were likely to confirm their clinical diagnosis, but also that in these high-risk patients, a noninvasive diagnostic strategy may help to reduce the need for FO-BAL with the attendant respiratory deterioration. Conceivably, routine use of the full range of noninvasive investigations may have a higher diagnostic yield, obviating the need for FO-BAL in a higher number of patients than in the present study. A study comparing patients managed with FO-BAL or with noninvasive investigations only would be of considerable interest. In addition, continuing advances in noninvasive diagnostic tests on various biological samples can be ex- pected to increase the diagnostic yield of noninvasive strategies in these high-risk hypoxemic patients (16, 35) .
Our results confirm that mortality is higher when the cause of ARF remains undetermined. The corollary to this fact is that recommendations should focus on the diagnostic strategy rather than on empirical treatment (3, 6, 36 ). An autopsy study in BMT recipients showed that only 27 of 96 pulmonary complications were diagnosed antemortem, indicating a need for better diagnostic strategies (37) .
Our study has several limitations. First, as mentioned above, the use of FO-BAL was at the clinician's discretion, and not all noninvasive investigations were performed routinely. However, previous studies also found no survival benefit with FO-BAL (3, 38) . Moreover, FO-BAL was independently associated with failure of NIMV and with a need for MV, supporting an adverse effect of the invasive strategy, as previously reported (1) . Second, we have focused our efforts to identify adverse events of FO-BAL in nonintubated patients. Indeed, respiratory status deterioration and subsequent need of ventilatory support clearly shifts patients' outcomes to a group with higher mortality. Third, BMT patients with pulmonary complication need to be treated aggressively, and the underlying etiology must be identified as early as possible. FO-BAL may not be the right choice, and studies are needed to investigate safety and diagnostic yield of pulmonary biopsies in this subset of patients.
In summary, in hypoxemic cancer patients with ARF, a noninvasive diagnostic strategy provides an etiologic diagnosis in a significant number of cases. FO-BAL may have an important role in the diagnostic work-up of selected critically ill cancer patients, but should be performed only after diligent analysis of its risks and benefits. Further controlled studies in nonintubated cancer patients with ARF are needed to evaluate the diagnostic yield of routinely performing the full range of noninvasive investigations, as well as the number of FO-BAL procedures and of intubations avoided with this strategy.
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